Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder
Koran LM, Aboujaoude E, Gamel NN
The Journal of clinical psychiatry · 49 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2009-06-30 · J Clin Psychiatry · vol. 70 · número 11 · págs. 1530–1535
- Editorial
- Physicians Postgraduate Press, Inc.
- Citado
- 79 citas · más que el 96% de estudios similares · 6.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Obsessive-Compulsive Spectrum Disorders · Schizophrenia research and treatment · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Palabras clave
- obsessive-compulsive disorder, d-amphetamine, treatment-resistant OCD, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, Yale-Brown Obsessive Compulsive Scale, adverse effects, treatment discontinuation
- MeSH
- humans, dextroamphetamine, caffeine, neurotransmitter uptake inhibitors, treatment outcome, drug therapy, combination, drug administration schedule, longitudinal studies, double-blind method, obsessive-compulsive disorder, psychiatric status rating scales, drug resistance, diagnostic and statistical manual of mental disorders, adult, middle aged, female, male, selective serotonin reuptake inhibitors
3 autores
- Koran Lm🇺🇸Stanford University
- Elias N. Aboujaoude
- Nona N. Gamel
Resumen
El texto original del estudio, en el idioma en que se publicó.
Introduction
Two small, double-blind, placebo-controlled, single-dose, crossover studies found dextroamphetamine (d-amphetamine) 30 mg clearly superior to placebo in relieving symptoms of obsessive-compulsive disorder (OCD). We conducted a 5-week, double-blind, caffeine-controlled study to test the hypothesis that d-amphetamine, added after an adequate selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) trial, would be more effective than caffeine in reducing residual OCD symptoms of moderate or greater severity.
Method
Between August 2006 and February 2008, we enrolled adults with DSM-IV OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of >or= 20 after >or= 12 weeks of adequate treatment with an SSRI or SNRI. Subjects were randomly assigned to double-blind d-amphetamine 30 mg/d or caffeine 300 mg/d added to their SSRI/SNRI and other medications. Responders (first week mean Y-BOCS score decrease of >or= 20%) entered the study's 4-week double-blind extension phase.
Results
We enrolled 24 subjects, 11 women and 13 men, with a mean (SD) age of 40 (13.2) years and mean baseline Y-BOCS scores of 26.5 (4.1) for the d-amphetamine group (n = 12) and 29.1 (4.0) for the caffeine group (n = 12). At the end of week 1, 6 of 12 d-amphetamine subjects (50%) and 7 of 12 caffeine subjects (58%) were responders. At week 5, the responders' mean Y-BOCS score decreases were, for the d-amphetamine group (last observation carried forward), 48% (range, 20%-80%); and, for the caffeine group, 55% (range, 27%-89%). Obsessive-compulsive disorder and depression improvement were independent. The double-blind remained intact. No subject discontinued the study due to side effects.
Conclusions
Larger, double-blind, placebo-controlled trials of both d-amphetamine and caffeine augmentation are needed in OCD subjects inadequately responsive to adequate doses of an SSRI or SNRI.
Trial registration
clinicaltrials.gov Identifier: NCT00363298.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.